Comparative Pharmacology
Head-to-head clinical analysis: CORTONE versus NASONEX 24HR ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTONE versus NASONEX 24HR ALLERGY.
CORTONE vs NASONEX 24HR ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, leading to decreased inflammation through inhibition of phospholipase A2, reduced cytokine production, and suppression of immune cell migration.
Glucocorticoid receptor agonist; inhibits inflammatory mediators including cytokines, chemokines, and adhesion molecules; reduces nasal inflammation.
Oral: 25-300 mg daily in 1-4 divided doses; typical initial dose 150-300 mg daily. IM/IV: 100-500 mg every 6-12 hours.
2 sprays (50 mcg/spray) per nostril once daily; total dose 200 mcg/day.
None Documented
None Documented
Terminal half-life: 8-12 hours (cortisone) but cortisone is a prodrug; active metabolite cortisol has half-life 1.5-2 hours. Clinical context: duration of action 8-12 hours due to prolonged receptor occupancy.
The terminal elimination half-life of mometasone furoate is approximately 5.8 hours. This short half-life supports once-daily dosing for intranasal use, but systemic accumulation is minimal with topical administration.
Renal: ~90% as metabolites (glucuronides and sulfates), ~5% unchanged; biliary/fecal: ~5%.
Mometasone furoate is predominantly eliminated via biliary/fecal excretion. After intravenous administration, approximately 74% of the dose is recovered in feces and about 8% in urine. The drug undergoes extensive hepatic metabolism, and metabolites are excreted primarily in bile.
Category C
Category C
Corticosteroid
Corticosteroid, Intranasal